These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Evaluation of pharmacokinetic drug-drug-interactions. Critical considerations of the relevance of pharmacokinetic drug-drug interactions of proton pump inhibitors in self medication]. Petersen KU Med Monatsschr Pharm; 2011 Aug; 34(8):270-8. PubMed ID: 21853881 [TBL] [Abstract][Full Text] [Related]
4. [Clinically relevant adverse drug interactions]. Martin-Facklam M; Haefeli WE Ther Umsch; 2000 Sep; 57(9):579-83. PubMed ID: 11036439 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic drug interactions in liver disease: An update. Palatini P; De Martin S World J Gastroenterol; 2016 Jan; 22(3):1260-78. PubMed ID: 26811663 [TBL] [Abstract][Full Text] [Related]
6. [Clinically relevant drug interactions in the elderly]. Jansen PA Ned Tijdschr Geneeskd; 2003 Mar; 147(13):595-9. PubMed ID: 12701392 [TBL] [Abstract][Full Text] [Related]
7. Mechanistic basis of adverse drug reactions: the perils of inappropriate dose schedules. Shah RR Expert Opin Drug Saf; 2005 Jan; 4(1):103-28. PubMed ID: 15709902 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic drug-drug interactions in the intensive care unit - single-centre experience and literature review. Łój P; Olender A; Ślęzak W; Krzych ŁJ Anaesthesiol Intensive Ther; 2017; 49(4):259-267. PubMed ID: 29027654 [TBL] [Abstract][Full Text] [Related]
9. The potential drug-drug interaction between proton pump inhibitors and warfarin. Henriksen DP; Stage TB; Hansen MR; Rasmussen L; Damkier P; Pottegård A Pharmacoepidemiol Drug Saf; 2015 Dec; 24(12):1337-40. PubMed ID: 26395871 [TBL] [Abstract][Full Text] [Related]
10. The time to act is now. Steel K Arch Intern Med; 2004 Aug 9-23; 164(15):1603-4. PubMed ID: 15302628 [No Abstract] [Full Text] [Related]
11. Common Drug Side Effects and Drug-Drug Interactions in Elderly Adults in Primary Care. Merel SE; Paauw DS J Am Geriatr Soc; 2017 Jul; 65(7):1578-1585. PubMed ID: 28326532 [TBL] [Abstract][Full Text] [Related]
13. Strategic proposals for avoiding toxic interactions with drugs for clinical use during development and after marketing of a new drug: pharmacokinetic consideration. Sugiyama Y; Iwatsubo T; Ueda K; Ito K J Toxicol Sci; 1996 Dec; 21(5):309-16. PubMed ID: 9035043 [No Abstract] [Full Text] [Related]
15. Clinical pharmacokinetics: current requirements and future perspectives from a regulatory point of view. Shah RR Xenobiotica; 1993 Nov; 23(11):1159-93. PubMed ID: 8310705 [TBL] [Abstract][Full Text] [Related]
17. A Survey of Neonatal Pharmacokinetic and Pharmacodynamic Studies in Pediatric Drug Development. Wang J; Avant D; Green D; Seo S; Fisher J; Mulberg AE; McCune SK; Burckart GJ Clin Pharmacol Ther; 2015 Sep; 98(3):328-35. PubMed ID: 25975723 [TBL] [Abstract][Full Text] [Related]
18. [How to identify and prevent pharmacokinetically relevant drug-drug interactions]. Ritter CA Med Monatsschr Pharm; 2009 Oct; 32(10):364-74; quiz 375-6. PubMed ID: 19886226 [TBL] [Abstract][Full Text] [Related]
19. Clinically relevant drug-drug interactions and the risk for drug adverse effects among home-dwelling older persons with and without type 2 diabetes. Ikäheimo I; Karjalainen M; Tiihonen M; Haanpää M; Kautiainen H; Saltevo J; Mäntyselkä P J Clin Pharm Ther; 2019 Oct; 44(5):735-741. PubMed ID: 31119771 [TBL] [Abstract][Full Text] [Related]
20. Evidence supporting the need for considering the effects of smoking on drug disposition and effectiveness in medication practices: a systematic narrative review. Sohn HS; Kim H; Song IS; Lim E; Kwon M; Ha JH; Kwon JW Int J Clin Pharmacol Ther; 2015 Aug; 53(8):621-34. PubMed ID: 26104035 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]